Ketorolac Tromethamine 15,30 mg/ml



In Adults

Pemrolac is indicated for the short-term (5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a
postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac, and Pemrolac is to be used only as continuation treatment, if necessary
The total combined duration of use of Pemrolac and ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses patients should be switched to alternative analgesics as soon as possible but Pemrolac therapy is not to exceed 5 days

In Children

The safety and efficacy of a single dose of pemrolac ampoule in children aged 2 to 16 years have been confirmed. Single dose pemrolac is effective in controlling relatively severe pain after surgery requiring opioid analgesics. Current data are lacking to confirm the efficacy of multiple doses of pemrolac in children